<DOC>
	<DOCNO>NCT00133900</DOCNO>
	<brief_summary>This study enrol men prostate cancer fail hormone therapy ( show rise prostate-specific antigen [ PSA ] level ) start new line chemotherapy . Blood drawn prior patient receive chemotherapy monthly thereafter 18 month disease progression , whichever occur first . The blood test find circulate tumor cell ( CTC ) count . The circulate tumor cell level study relation patient 's overall survival . Serum also collect PSA test , additional blood sample draw test circulate endothelial cell RNA isolate future gene expression test .</brief_summary>
	<brief_title>Circulating Tumor Cells Survival Hormone Refractory Prostate Cancer ( HRPC ) Patients Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Age &gt; = 18 year Pathological diagnosis adenocarcinoma prostate First later line chemotherapy Serum testosterone &lt; 50ng/mL ECOG 02 Serum PSA &gt; = 5ng/mL PSA progression ( 2 rise reference value ) Bone scan within 60 day enrollment Computed tomography ( CT ) scan If measurable disease , bone scan every 68 month Systemic radiation Prior history carcinoma within last 5 year , except nonmelanoma skin cancer Brain metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>hormone refractory prostate cancer</keyword>
</DOC>